Chris Alexander
Endocrinology, Diabetes & Metabolism · Denison, TXNPI 1366763757
Payments from drug & device makers
Across 676 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$2K
- Amgen$1K
- Abbott$1K
- AstraZeneca$910
- Boehringer Ingelheim$866
- plus $7K from 32 others
What the payments were for
- Travel & lodging$7055%
- Food & beverage$14,21692%
- Education$5724%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 27 | $2,230 |
| Novo Nordisk | 78 | $2,181 |
| Amgen | 78 | $1,474 |
| Abbott | 53 | $1,192 |
| AstraZeneca(2 entities) | 43 | $910 |
| Boehringer Ingelheim | 58 | $866 |
| Lilly USA, LLC | 62 | $832 |
| Corcept Therapeutics | 25 | $622 |
| AbbVie | 38 | $615 |
| Dexcom, Inc. | 22 | $521 |
| Xeris Pharmaceuticals, Inc. | 26 | $507 |
| Insulet Corporation | 23 | $496 |
| Merck | 28 | $403 |
| Novartis | 6 | $344 |
| Radius Health, Inc. | 11 | $343 |
| Esperion Therapeutics, Inc. | 6 | $283 |
| Sanofi-aventis U.S. LLC | 15 | $261 |
| Tandem Diabetes Care, Inc. | 11 | $221 |
| IBSA Pharma Inc. | 11 | $178 |
| Ascendis Pharma Endocrinology Inc | 6 | $142 |
| Neurocrine Biosciences, Inc. | 5 | $117 |
| Amneal Pharmaceuticals LLC | 6 | $110 |
| Johnson & Johnson | 6 | $97 |
| Antares Pharma, Inc. | 5 | $78 |
| BETA Bionics, Inc. | 6 | $73 |
| Ascensia Diabetes Care US Inc. | 2 | $60 |
| Amarin Pharma, Inc. | 3 | $49 |
| Kyowa Kirin, Inc. | 2 | $43 |
| Shire North American Group Inc | 2 | $37 |
| Amphastar Pharmaceuticals, Inc. | 2 | $35 |
| Pfizer | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $32 |
| Sequel Med Tech, LLC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| GSK | 1 | $15 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| RGH Enterprises LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,598
- FREESTYLE LIBRE 3$413
- Ozempic$335
- DEXCOM G6 TRANSMITTER$261
- FreeStyle Libre 2$157
- MINIMED 770G$138
- Korlym$126
- NEXLETOL$125
- InPen$123
- Prolia$104
- GVOKE PFS$104
How this compares
$15,493 in reported general payments places this provider in the 70th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 727 | $1,159,616 |
| MounjaroTirzepatide | 320 | $532,676 |
| JardianceEmpagliflozin | 337 | $387,032 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 119 | $145,924 |
| TrulicityDulaglutide | 65 | $106,596 |
| FarxigaDapagliflozin Propanediol | 69 | $95,680 |
| Tresiba Flextouch U-100Insulin Degludec | 120 | $84,985 |
| RybelsusSemaglutide | 34 | $81,441 |
| JanuviaSitagliptin Phosphate | 91 | $71,239 |
| ProliaDenosumab | 31 | $54,401 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $45,585 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $42,232 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 39 | $37,923 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 33 | $35,733 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 38 | $30,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $2,181 | $1,292,014834 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro | $832 | $680,746489 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $866 | $415,403369 claims |
| AstraZenecaFarxiga | $910 | $95,68069 claims |
| MerckJanuvia | $403 | $71,23991 claims |
| AmgenProlia | $1,474 | $54,40131 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $261 | $37,92339 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $110 | $5,480555 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Denison
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.